惡性嗜鉻細(xì)胞瘤的治療-資料下載頁
2025-05-26 08:57本頁面
【正文】 , may result in additional benefit ? (Sisson et al. 1999) 2022/6/23 28 Alternative of Current Therapy ? Surgery ? Radiopharmaceuticals ? Combined Chemotherapy ? Arterial Embolization 2022/6/23 29 ? Only sparse data on chemotherapeutic regimens are available, most of them in reports of few cases ? The most wellestablished regimen is CVD (Averbuch et al. 1988) ? CTX 750mg/m2 d1, VCR , Dacarbazine 600mg/m2 d1,2 ? Cycle 21 days 2022/6/23 30 ? The CVD regimen was based on the treatment for advanced neuroblastoma. ? This regimen has been reported to produce good responses in malignant pheochromocytoma, but the median duration of remission is 21 months ? Complete longterm disease remissions with chemotherapy have not been reported. 2022/6/23 31 Alternative of Current Therapy ? Surgery ? Radiopharmaceuticals ? Combined Chemotherapy ? Transcatheter Arterial Embolization 2022/6/23 32 ? TAE has been successfully performed in the treatment of malignant PCC with liver metastases ? The therapeutic effects of TAE have been demonstrated to be enhanced by the bination therapy with anticancer chemotherapy 2022/6/23 33 ? Mitomycin C has been successfully used in TAE for liver metastasis in several cases of malignant PCC. 2022/6/23 34 2022/6/23 35 Malignant pheochromocytoma: past, present and future Past Present Future Adrenergic blockers, αmethylparatyrosine amp。 use of other drugs for symptomatic relief Surgical debulking。 131IMIBG radiotherapy。 Chemotherapy。 Chemoembolization Molecular targeting, cancer vaccines, gene therapy
黨政相關(guān)相關(guān)推薦
鄂ICP備17016276號(hào)-1